Skip to main content

Advertisement

Fig. 1 | Malaria Journal

Fig. 1

From: New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model

Fig. 1

Seroprevalence of GC44, GC45 and GC46 in North American and African adults. a The seroprevalence (NAb titre >32) of HuAd5, GC44, GC45 and GC46 was determined in 250 adults living in the United States, 90 adults in Kenya and 100 adults in Ghana. In Kenya, the seroprevalence was 69, 20, 9 and 20% for HuAd5, GC44, GC45 and GC46, respectively. In Ghana, the seroprevalence was 91, 14, 14 and 18% for HuAd5, GC44, GC45 and GC46, respectively. The NAb titres of individuals from Kenya (b) and Ghana (c) were segregated into four categories; <32, 32–200, 200–1000 or >1000. Higher NAb titres are represented by progressively darker colours. 16% of the Kenyan samples and 36% of the Ghanaian samples had NAb titres against HuAd5 that were >1000, whereas none of the samples had comparable titres against GC44, GC45 or GC46. Additionally, 44% of the Kenyan samples and 77% of the Ghanaian samples had NAb titres against HuAd5 that were >200, whereas only 1, 1 and 3% of the Kenyan samples and 1, 1 and 2% of the Ghanaian samples had comparable titres against GC44, GC45 and GC46

Back to article page